The Experts below are selected from a list of 39867 Experts worldwide ranked by ideXlab platform

Marcel Nimni - One of the best experts on this subject based on the ideXlab platform.

  • the effect of thrombin activation of platelet rich Plasma on demineralized bone matrix osteoinductivity
    Journal of Bone and Joint Surgery American Volume, 2009
    Co-Authors: Jennifer E Woodellmay, Zhi Yang, Michael Ponticiello, Marcel Nimni
    Abstract:

    Background: Demineralized bone matrix is an osteoinductive and osteoconductive material that is often used in orthopaedic surgery to induce bone formation. Autologous Platelet-Rich Plasma, which contains proliferative and chemoattractant growth factors, has been used as a demineralized bone matrix adjuvant with mixed results. One variable during clinical use appears to be whether the Platelet-Rich Plasma is activated with thrombin or is implanted in a liquid form with intact platelets. The objective of the present study was to determine if Platelet-Rich Plasma can increase the osteoinductivity of demineralized bone matrix when used without thrombin activation. Methods: The bioactivity of the demineralized bone matrix was evaluated in vitro by determining alkaline phosphatase production by C2C12 myoblast cells. The effect of thrombin activation on Platelet-Rich Plasma was studied in vitro by evaluating osteosarcoma and bone marrow stromal cells for cell number and transforming growth factor-β1 activation. Demineralized bone matrices supplemented with Platelet-Rich Plasma, with or without thrombin activation, were implanted intramuscularly in athymic rats and were examined at fourteen, twenty-eight, and fifty-six days. Histological samples were analyzed for osteogenesis and chondrogenesis. Osteogenesis was further characterized on the basis of alkaline phosphatase activity. Results: In vitro, thrombin triggered an immediate release of growth factors from the Platelet-Rich Plasma, and the Platelet-Rich Plasma increased the number of both osteosarcoma and stromal cells in a dose-dependent manner. Thrombin activation of the Platelet-Rich Plasma eliminated such stimulatory effects. In vivo, the Platelet-Rich Plasma stimulated chondrogenesis on Day 14 and osteogenesis on Days 28 and 56, whereas thrombin-activated Platelet-Rich Plasma acted as an inhibitor of such events. In addition, inflammatory cells were detected in demineralized bone matrix samples that were mixed with thrombin-activated Platelet-Rich Plasma. These cells were not present in matrix mixed with Platelet-Rich Plasma alone. Conclusions: Platelet-Rich Plasma significantly increased in vivo demineralized bone matrix osteoinductivity only when used without thrombin activation. Clinical Relevance: Platelet-Rich Plasma has the potential to increase the osteoinductivity of demineralized bone matrix in clinical applications. On the other hand, its activation by thrombin immediately prior to implantation significantly inhibits this activity.

Jennifer E Woodellmay - One of the best experts on this subject based on the ideXlab platform.

  • the effect of thrombin activation of platelet rich Plasma on demineralized bone matrix osteoinductivity
    Journal of Bone and Joint Surgery American Volume, 2009
    Co-Authors: Jennifer E Woodellmay, Zhi Yang, Michael Ponticiello, Marcel Nimni
    Abstract:

    Background: Demineralized bone matrix is an osteoinductive and osteoconductive material that is often used in orthopaedic surgery to induce bone formation. Autologous Platelet-Rich Plasma, which contains proliferative and chemoattractant growth factors, has been used as a demineralized bone matrix adjuvant with mixed results. One variable during clinical use appears to be whether the Platelet-Rich Plasma is activated with thrombin or is implanted in a liquid form with intact platelets. The objective of the present study was to determine if Platelet-Rich Plasma can increase the osteoinductivity of demineralized bone matrix when used without thrombin activation. Methods: The bioactivity of the demineralized bone matrix was evaluated in vitro by determining alkaline phosphatase production by C2C12 myoblast cells. The effect of thrombin activation on Platelet-Rich Plasma was studied in vitro by evaluating osteosarcoma and bone marrow stromal cells for cell number and transforming growth factor-β1 activation. Demineralized bone matrices supplemented with Platelet-Rich Plasma, with or without thrombin activation, were implanted intramuscularly in athymic rats and were examined at fourteen, twenty-eight, and fifty-six days. Histological samples were analyzed for osteogenesis and chondrogenesis. Osteogenesis was further characterized on the basis of alkaline phosphatase activity. Results: In vitro, thrombin triggered an immediate release of growth factors from the Platelet-Rich Plasma, and the Platelet-Rich Plasma increased the number of both osteosarcoma and stromal cells in a dose-dependent manner. Thrombin activation of the Platelet-Rich Plasma eliminated such stimulatory effects. In vivo, the Platelet-Rich Plasma stimulated chondrogenesis on Day 14 and osteogenesis on Days 28 and 56, whereas thrombin-activated Platelet-Rich Plasma acted as an inhibitor of such events. In addition, inflammatory cells were detected in demineralized bone matrix samples that were mixed with thrombin-activated Platelet-Rich Plasma. These cells were not present in matrix mixed with Platelet-Rich Plasma alone. Conclusions: Platelet-Rich Plasma significantly increased in vivo demineralized bone matrix osteoinductivity only when used without thrombin activation. Clinical Relevance: Platelet-Rich Plasma has the potential to increase the osteoinductivity of demineralized bone matrix in clinical applications. On the other hand, its activation by thrombin immediately prior to implantation significantly inhibits this activity.

Thomas S. Roukis - One of the best experts on this subject based on the ideXlab platform.

  • Bone and wound healing augmentation with Platelet-Rich Plasma.
    Clinics in Podiatric Medicine and Surgery, 2009
    Co-Authors: Simon E. Smith, Thomas S. Roukis
    Abstract:

    Over the past two decades, autologous platelets that have been sequestered, concentrated, and mixed with thrombin to generate growth factor–concentrated Platelet-Rich Plasma for application to bone and wounds to aide healing have been a subject of great interest. This article reviews the literature related to the use of autologous Platelet-Rich Plasma in bone and wound healing, and reviews the processes necessary to secure a high concentration of viable platelets. Although not yet definitive, autologous Platelet-Rich Plasma has been shown to be safe, reproducible, and effective in mimicking the natural process of bone and wound healing.

  • autologous platelet rich Plasma for wound and osseous healing a review of the literature and commercially available products
    Advances in Therapy, 2006
    Co-Authors: Thomas S. Roukis, Thomas Zgonis, Breck Tiernan
    Abstract:

    The application of autologous platelets that have been sequestered, concentrated, and mixed with thrombin to create growth factor-concentrated, autologous Platelet-Rich Plasma for application to soft tissue wounds and for osseous healing has been a subject of great interest for much of the past 2 decades. Autologous Platelet-Rich Plasma, which consists of both quantitative and qualitative components, has the greatest potency or ability to produce the desired effect. Manufacturers prepare autologous Platelet-Rich Plasma with the ultimate goal of maximizing its benefits while minimizing potential risks. Unfortunately, the manufacturing processes for autologous Platelet-Rich Plasma are highly variable, and the types of proprietary systems available on the market for soft tissue and osseous applications are numerous. The authors provide here an in-depth review of commercially available systems for delivery of autologous Platelet-Rich Plasma that emphasizes the subtle yet important differences among systems. In addition, a detailed review of the literature regarding the use of autologous Platelet-Rich Plasma in soft tissue and osseous healing is provided. Although findings are not yet conclusive, autologous Platelet-Rich Plasma has been shown to be safe, reproducible, and effective in mimicking the natural processes of soft tissue wound and osseous healing.

Breck Tiernan - One of the best experts on this subject based on the ideXlab platform.

  • autologous platelet rich Plasma for wound and osseous healing a review of the literature and commercially available products
    Advances in Therapy, 2006
    Co-Authors: Thomas S. Roukis, Thomas Zgonis, Breck Tiernan
    Abstract:

    The application of autologous platelets that have been sequestered, concentrated, and mixed with thrombin to create growth factor-concentrated, autologous Platelet-Rich Plasma for application to soft tissue wounds and for osseous healing has been a subject of great interest for much of the past 2 decades. Autologous Platelet-Rich Plasma, which consists of both quantitative and qualitative components, has the greatest potency or ability to produce the desired effect. Manufacturers prepare autologous Platelet-Rich Plasma with the ultimate goal of maximizing its benefits while minimizing potential risks. Unfortunately, the manufacturing processes for autologous Platelet-Rich Plasma are highly variable, and the types of proprietary systems available on the market for soft tissue and osseous applications are numerous. The authors provide here an in-depth review of commercially available systems for delivery of autologous Platelet-Rich Plasma that emphasizes the subtle yet important differences among systems. In addition, a detailed review of the literature regarding the use of autologous Platelet-Rich Plasma in soft tissue and osseous healing is provided. Although findings are not yet conclusive, autologous Platelet-Rich Plasma has been shown to be safe, reproducible, and effective in mimicking the natural processes of soft tissue wound and osseous healing.

Jorge L Alio - One of the best experts on this subject based on the ideXlab platform.

  • Solid Platelet Rich Plasma in Corneal Surgery
    Ophthalmology and Therapy, 2016
    Co-Authors: Francisco Arnalich, Alejandra E Rodriguez, Alvaro Luque-rio, Jorge L Alio
    Abstract:

    Solid eye Platelet-Rich Plasma (E-PRP) concentrates platelets in a small volume of Plasma which contains a high concentration of important growth factors and cell adhesion molecules. These cell adhesion molecules and growth factors occupy a major role in wound healing and enhance the physiological procedure at the site of the injury or the surgery. There are different materials used to tectonically maintain the solid clot attached at the site where treatment is necessary. Although AM may be used for this purpose, other biomaterials such a bovine pericardium or autologous fibrin membrane are at least as effective with less interdonor variations, no biological hazards, providing a better surgical alternative than the biologically so variable amniotic membrane patch. Solid Platelet-Rich Plasma in the form obtained in ophthalmology, E-PRP, is a reliable and effective surgical coadjuvant to promote corneal wound healing in severe corneal ulcers and corneal perforations, and may be associated with other ocular surface reconstruction procedures. Funding Supported in part by a grant from the Spanish Ministry of Science and Innovation, Centro para el Desarrollo Tecnológico Industrial (CDTI), CENIT: “Customized Eye Care”, CeyeC (CEN-20091021).

  • use of autologous platelet rich Plasma in the treatment of dormant corneal ulcers
    Ophthalmology, 2007
    Co-Authors: Jorge L Alio, Marta Abad, Alberto Artola, Jose L Rodriguezprats, Silvia Pastor, Jose Ruizcolecha
    Abstract:

    Purpose To investigate the potential role of autologous Platelet-Rich Plasma in promoting healing in dormant corneal ulcers. Design Prospective, consecutive, interventional, noncomparative, nonrandomized, observational study. Participants Forty eyes of 38 patients with dormant corneal ulcers. Methods Autologous Platelet-Rich Plasma was used in a total of 40 eyes with dormant corneal ulcers divided into 2 groups: group I, 26 eyes treated with topical eyedrops of autologous Platelet-Rich Plasma (12 neurotrophic, 9 herpetic, and 5 immunological ulcers), and group II, 14 eyes treated surgically with a solid clot of autologous Platelet-Rich Plasma combined with amniotic membrane transplantation in perforated corneas or with impending perforation. The treatment was used in patients with chronic nonhealing ulcers (mean, 2 years of evolution) that had been unresponsive to conventional topical therapy. Autologous blood from each patient was obtained by venipuncture, and Platelet-Rich Plasma was prepared from each blood sample without additives. Main Outcome Measures Ulcer size, inflammation, healing, visual acuity, and patient's subjective symptoms. Results Autologous Platelet-Rich Plasma promoted healing of ulcers. In group I, 13 eyes healed, 11 eyes improved significantly, and 2 eyes showed no change. In group II, 10 eyes healed and 4 eyes improved significantly. Inflammation and subjective symptoms, particularly pain, improved in all patients. Vision remained stable or improved in all cases. Conclusion Autologous Platelet-Rich Plasma promoted healing of dormant corneal ulcers even in eyes threatened by corneal perforation and was accompanied by a reduction in pain and inflammation.

  • symptomatic dry eye treatment with autologous platelet rich Plasma
    Ophthalmic Research, 2007
    Co-Authors: Jorge L Alio, Silvia Pastor, Jose R Colecha, Alejandra E Rodriguez, Alberto Artola
    Abstract:

    Background: Autologous Platelet-Rich Plasma (PRP) has been proven to be very effective on tissue regeneration and wound healing. Here we investigate the potential use of PRP in the